Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo

Table 1 Antimicrobial susceptibility profiles of ADS024

Antimicrobial	MIC in mg/L (interpretation) for ADS024
	CO-33 ADS024 SYD
Ampicillin	≤ 0.03 (S)
Chloramphenicol	2 (S)
Ciprofloxacin	≤ 0.03 (S)
Clindamycin	0.25 (S)
Erythromycin	0.12 (S)
Fidaxomicin	4
Gentamicin	≤ 0.06 (S)
Kanamycin	≤ 0.50 (S)
Linezolid	0.5
Metronidazole (aerobic)	> 64.00
Metronidazole (anaerobic)	64
Neomycin	≤ 0.12
Penicillin	0.06 (S)
Quinupristin–dalfopristin	2
Rifampicin	0.25 (S)
Streptomycin	2 (S)
Tetracycline	2 (S)
Trimethoprim	≤ 0.25
Vancomycin	≤ 0.25 (S)

Four samples of ADS024 were tested. Shown here are the results using ADS024 from the master cell bank (CO-33 ART24 SYD; frozen). MIC: Minimum inhibitory concentration; S: Susceptible.